Introduction: Tuberous sclerosis complex (TSC) is a genetic disorder that can arise from sporadic or inherited mutations in TSC1 or TSC2 genes. It is characterized by tumors in multiple organs that result in broad clinical manifestations, usually affecting the central nervous system. Diagnosis is based upon clinical criteria that require careful clinical examination along with imaging and the availability of genetic testing to assess gene mutations linked to this disorder. We present a familial case of tuberous sclerosis complex with multiple subtle clinical manifestations and novel TSC1 mutation that were diagnosed in adulthood. This report adds to the growing literature on TSC1 gene by correlating specific nucleotide substitutions with possible secondary clinical manifestations.
Introduction
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder that affects about 1:6,000 individuals. About two-thirds of TSC cases are sporadic, representing spontaneous mutations, while one-third are inherited [1] . It is characterized by the development of distinctive tumors termed hamartomas in multiple organ systems such as brain, retina, skin, heart, lungs, and kidneys [2] . TSC has been associated with mutations in either the TSC1 on chromosome 16p13.3 or TSC2 on chromosome 9q34, which encode hamartin and tuberin, respectively. The hamartin/tuberin complex formation is responsible for the signaling pathway that regulates a key inhibitor of cell growth and metabolism known as mammalian target of rapamycin complex 1 (mTORC1) [3] .
TSC has high variability in clinical presentation and findings. Diagnosis of TSC is based on the presence of at least two major clinical features, or one major and two minor clinical features [4] . Although patients may present with early manifestations of seizures, intellectual disability, and skin abnormalities, fewer than 30% have all three and 6% have none [2] . Previous studies have revealed that patients with subtle TSC findings remain either without diagnosis or do not present symptoms until later in life (i.e., TSC identified in a parent after an affected child was diagnosed).
We are reporting a familial case of TSC with a novel TSC1 mutation in both affected individuals presenting with mild clinical manifestations.
Case Presentation
A 21-year-old Hispanic female presented with history of epilepsy, with seizure onset at age 6. Her seizures are well controlled with medication. Her physical examination revealed a fibrous cephalic plaque (3.5 cm) and neurological examination was normal. On ophthalmic examination, small hamartomatous lesions about 200 to 300 microns were found. Baseline EEG showed right fronto-temporal intermittent discharge activity. A non-contrast brain CT depicted a single subependymal nodule ( Figure 1A ) and brain MRI demonstrated a subcortical tuber with associated radial migration line ( Figure 1B) . Renal ultrasound and echocardiogram results were normal and no overt pulmonary signs or symptoms ( Figure 1C ).
Her mother is 51 years old with long-standing history of epilepsy controlled with medication. On dermatological examination, there were inflamed pedunculated papules on the neck, trunk, and axillae consistent with soft fibromas. Multiple cherry angiomas and benign nevi were present on the trunk in addition to a hypomelanotic macule in the axilla ( Figure 1F ). Ophthalmic examination showed a few small lesions consistent with retinal hamartomas. Brain MRI demonstrated a single subependymal nodule, subcortical tubers ( Figure 1D ), and radiation migration lines. Renal ultrasound, echocardiogram, and EEG results were normal and no overt pulmonary signs or symptoms ( Figure 1E ).
Genetic testing was conducted by Athena Diagnostics, Inc. TSC1 and TSC2 genes were analyzed for deletions by using Multiplex Ligation-mediated Probe Amplification (MLPA) of genomic DNA. DNA sequence analysis was performed by PCR amplification of purified genomic DNA, followed by automated DNA sequencing of the coding region and the 10 bases of intronic DNA surrounding each exon containing the highly conserved exon-intron splice junctions. This test detected a DNA sequence variant TSC1 IVS18-6 G>A that might interfere with normal splicing in both mother and daughter.
Discussion
TSC is characterized by multisystem involvement that results in a wide range of manifestations. Neurologic symptoms are common in individuals diagnosed with TSC, as epilepsy occurs in 80-90%, cognitive impairment in 50%, and neurobehavioral disorders in >60% of cases [5] . However, milder forms of the disorder may lead to diagnosis during adolescence and adulthood when more evident manifestations are present.
We describe a mother and daughter with no overt cognitive changes and no other family history (neither had siblings) suggestive of TSC. The presenting symptom in both individuals was epilepsy and other clinical manifestations were later identified as part of TSC. They both fulfill definite diagnostic criteria as per the most recent diagnostic criteria [4] . The mother has subependymal nodules and cortical dysplasia as major features in addition to suspected retinal hamartomas and some dermatological findings, and the daughter has subependymal nodules, cortical dysplasia, fibrous plaque on scalp, and small retinal hamartomas.
Previous studies have reported that approximately 10-30% of all TSC cases are caused by TSC1 mutations [6] . TSC1 mutations are associated with a less severe phenotype as compared to TSC2 gene [7] . Genetic testing in mother and daughter indicated a single nucleotide substitution of A-to-G that is likely pathogenic in TSC1 gene not previously described in the literature. These findings along with the clinical manifestations suggest this is a novel TSC-causing mutation.
Conclusion
This report describes a novel TSC1 mutation found in a mother and daughter with history of epilepsy and clinical criteria of TSC. Although it is not certain that the genetic test findings correlate with TSC, these patients' clinical manifestations and family history are suggestive of its association. This novel DNA sequence variant expands the spectrum of known TSC1 gene mutations. It supports the growing literature that familial cases with TSC1 mutations might have milder clinical manifestations. Misdiagnosis of these individuals can be avoided with careful clinical examination and genetic testing to be able to provide prompt treatment and management.
